Corium International Inc  

(Public, NASDAQ:CORI)   Watch this stock  
Find more results for CORI
5.22
-0.13 (-2.43%)
After Hours: 5.23 +0.01 (0.19%)
Feb 9, 4:07PM EST  
NASDAQ real-time data - Disclaimer
Currency in USD
Range 4.62 - 5.34
52 week 4.62 - 16.29
Open 5.01
Vol / Avg. 109,134.00/76,168.00
Mkt cap 108.67M
P/E     -
Div/yield     -
EPS -1.52
Shares 22.22M
Beta     -
Inst. own 87%
May 5, 2016
Q2 2016 Corium International Inc Earnings Release (Estimated) - 4:00PM EDT - Add to calendar
Feb 10, 2016
Corium International Inc at Leerink Partners Global Healthcare Conference - 3:30PM EST - Add to calendar
Feb 8, 2016
Q1 2016 Corium International Inc Earnings Call
Feb 8, 2016
Q1 2016 Corium International Inc Earnings Release
Nov 12, 2015
Q4 2015 Corium International Inc Earnings Call - Webcast
Nov 12, 2015
Q4 2015 Corium International Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '15) 2015
Net profit margin -93.19% -69.52%
Operating margin -72.20% -51.38%
EBITD margin - -44.90%
Return on average assets -43.28% -34.18%
Return on average equity -231.46% -120.75%
Employees 247 -
CDP Score - -

Address

235 Constitution Dr
MENLO PARK, CA 94025-1108
United States - Map
+1-650-2988012 (Phone)
+1-302-6555049 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Corium International, Inc. is a commercial-stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty pharmaceutical products that leverage its broad experience in transdermal and transmucosal delivery systems. The Company’s marketed products are Clonidine Transdermal Delivery System, or TDS, Fentanyl TDS and four Crest Advanced Seal Whitestrips products. Its transdermal technologies are MicroCor, a biodegradable microstructure patch technology for active delivery of proteins, peptides and vaccines large molecules that require active transport through the skin, and Corplex, a novel adhesive system and patch technology for delivery of small molecules that may otherwise be difficult to formulate and deliver.

Officers and directors

David L. Greenwood Chairman of the Board
Age: 64
Bio & Compensation  - Reuters
Peter D. Staple President, Chief Executive Officer, Director
Age: 64
Bio & Compensation  - Reuters
Robert S. Breuil Chief Financial Officer
Age: 51
Bio & Compensation  - Reuters
Parminder Singh Ph.D. Chief Technology Officer, Vice President - Research & Development
Age: 52
Bio & Compensation  - Reuters
Joseph J. Sarret M.D., J.D. Chief Business Officer
Age: 48
Bio & Compensation  - Reuters
Robert W. Thomas Lead Independent Director
Age: 54
Bio & Compensation  - Reuters
Eric H. Bjerkholt Independent Director
Age: 56
Bio & Compensation  - Reuters
Bhaskar Chaudhuri Ph.D. Independent Director
Age: 61
Bio & Compensation  - Reuters
Ronald W. Eastman Independent Director
Age: 63
Bio & Compensation  - Reuters
Phyllis I. Gardner M.D. Independent Director
Age: 65
Bio & Compensation  - Reuters